AstraZeneca’s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy
AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval...
NASDAQ: AZN
HBM and AstraZeneca Deepen ADC/TCE Collaboration as AstraZeneca Exercises License Options
HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration...
AstraZeneca Posts 11% Y/Y Revenue Rise to $43.24 bn in First Nine‑Months of 2025
AstraZeneca (AZ, NASDAQ: AZN) released its third‑quarter and nine‑month 2025 financial results, showing total revenues...
AstraZeneca Launches Sixth Global R&D Center in Beijing to Accelerate China Investments
AstraZeneca (AZ, NASDAQ: AZN) announced on October 25, 2025, the launch of its sixth Global...
AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase III DESTINY‑Breast11 results at...
AstraZeneca China Integrates Symbicort and Breztri Sales Teams in New Organizational Shake‑Up
AstraZeneca (AZ; NASDAQ: AZN) announced a strategic re‑alignment of its respiratory inhalation portfolio in China, consolidating...
AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure
AstraZeneca plc (AZ; NASDAQ: AZN) has unveiled a plan to standardise its share‑listing structure across...
AstraZeneca and Daiichi Sankyo Submit Priority‑Review sBLA for Enhertu as First‑Line Therapy for HER2‑Positive Breast Cancer
AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have filed a supplemental Biologics License...
Burning Rock Secures Japanese Approval for OncoGuide OncoScreen Plus CDx, Enabling Capivasertib Therapy
Burning Rock Ltd. (NASDAQ: BNR), a China‑based medical‑technology company, announced that its OncoGuide OncoScreen Plus CDx...
AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy
AstraZeneca (AZ; NASDAQ: AZN) China announced a sweeping re‑organisation that removes the country‑level Head of...
AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the launch of Ultomiris (ravulizumab), a...
AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts
On September 12, 2025, AstraZeneca (AZ; NASDAQ: AZN) confirmed it has paused its GBP 200m...
DATROWAY Approved in China for HR-Positive, HER2-Negative Breast Cancer
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) announced that DATROWAY has been approved...
AstraZeneca’s Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced the official approval of a new indication...
AstraZeneca’s Ultomiris Gains NMPA Approval for Neuromyelitis Optica Spectrum Disorder
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA)...
AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies
UK-based AstraZeneca’s (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a...
AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by...
AstraZeneca’s FLAURA2 Study Confirms Osimertinib Combo’s Survival Benefit in NSCLC
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced the final overall survival (OS) results from the Phase III...
Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have submitted a supplemental new-drug application...
AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...